CVS Health Corporation (NYSE:CVS) Shares Sold by Plimoth Trust Co. LLC

Plimoth Trust Co. LLC cut its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 83.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,060 shares of the pharmacy operator's stock after selling 24,901 shares during the quarter. Plimoth Trust Co. LLC's holdings in CVS Health were worth $343,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CVS. LaFleur & Godfrey LLC raised its position in CVS Health by 49.9% in the fourth quarter. LaFleur & Godfrey LLC now owns 4,836 shares of the pharmacy operator's stock worth $217,000 after acquiring an additional 1,610 shares in the last quarter. Principal Securities Inc. raised its position in CVS Health by 3.2% in the fourth quarter. Principal Securities Inc. now owns 27,881 shares of the pharmacy operator's stock worth $1,252,000 after acquiring an additional 859 shares in the last quarter. Allworth Financial LP raised its position in CVS Health by 23.7% in the fourth quarter. Allworth Financial LP now owns 21,795 shares of the pharmacy operator's stock worth $978,000 after acquiring an additional 4,182 shares in the last quarter. Atria Wealth Solutions Inc. raised its position in CVS Health by 62.3% in the fourth quarter. Atria Wealth Solutions Inc. now owns 62,160 shares of the pharmacy operator's stock worth $2,790,000 after acquiring an additional 23,849 shares in the last quarter. Finally, Kestra Investment Management LLC raised its position in CVS Health by 25.5% in the fourth quarter. Kestra Investment Management LLC now owns 6,806 shares of the pharmacy operator's stock worth $306,000 after acquiring an additional 1,384 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Price Performance

Shares of CVS traded down $0.15 during trading hours on Friday, reaching $66.69. 11,828,346 shares of the company traded hands, compared to its average volume of 10,963,290. The company has a quick ratio of 0.63, a current ratio of 0.82 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $84.36 billion, a PE ratio of 15.92, a price-to-earnings-growth ratio of 0.96 and a beta of 0.56. CVS Health Corporation has a fifty-two week low of $43.56 and a fifty-two week high of $72.51. The stock has a fifty day simple moving average of $64.92 and a 200 day simple moving average of $60.40.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The business had revenue of $94.59 billion for the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.31 earnings per share. As a group, research analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

Insider Activity at CVS Health

In related news, Director Guy P. Sansone acquired 1,570 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were acquired at an average price of $63.70 per share, with a total value of $100,009.00. Following the completion of the purchase, the director now directly owns 12,007 shares in the company, valued at approximately $764,845.90. The trade was a 15.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.22% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on CVS shares. Wells Fargo & Company reiterated an "overweight" rating and issued a $84.00 price objective (up previously from $76.00) on shares of CVS Health in a research report on Tuesday, May 6th. UBS Group increased their price objective on CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a research report on Friday, May 2nd. Mizuho raised their price target on CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Royal Bank Of Canada raised their price target on CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a research report on Monday, May 5th. Finally, Barclays set a $79.00 price target on CVS Health and gave the company an "overweight" rating in a research report on Monday, June 2nd. Two analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, CVS Health currently has a consensus rating of "Moderate Buy" and an average target price of $74.75.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.